<?xml version="1.0" encoding="UTF-8"?>
<ref id="B50">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Tavares</surname>
    <given-names>L. P.</given-names>
   </name>
   <name>
    <surname>Garcia</surname>
    <given-names>C. C.</given-names>
   </name>
   <name>
    <surname>Machado</surname>
    <given-names>M. G.</given-names>
   </name>
   <name>
    <surname>Queiroz-Junior</surname>
    <given-names>C. M.</given-names>
   </name>
   <name>
    <surname>Barthelemy</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Trottein</surname>
    <given-names>F.</given-names>
   </name>
   <etal/>
  </person-group> (
  <year>2017</year>). 
  <article-title>CXCR1/2 antagonism is protective during influenza and post-influenza pneumococcal infection.</article-title>
  <source>
   <italic>Front. Immunol.</italic>
  </source>
  <volume>8</volume>:
  <issue>1799</issue>. 
  <pub-id pub-id-type="doi">10.3389/fimmu.2017.01799</pub-id>
  <?supplied-pmid 29326698?>
  <pub-id pub-id-type="pmid">29326698</pub-id>
 </mixed-citation>
</ref>
